PL1750704T3 - Pochodne mocznika jako antagoniści receptora P2Y1 użyteczne w leczeniu stanów zakrzepowych - Google Patents
Pochodne mocznika jako antagoniści receptora P2Y1 użyteczne w leczeniu stanów zakrzepowychInfo
- Publication number
- PL1750704T3 PL1750704T3 PL05779448T PL05779448T PL1750704T3 PL 1750704 T3 PL1750704 T3 PL 1750704T3 PL 05779448 T PL05779448 T PL 05779448T PL 05779448 T PL05779448 T PL 05779448T PL 1750704 T3 PL1750704 T3 PL 1750704T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- thrombotic conditions
- receptor useful
- antagonists
- urea
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57028804P | 2004-05-12 | 2004-05-12 | |
US66573505P | 2005-03-28 | 2005-03-28 | |
US11/126,567 US7550499B2 (en) | 2004-05-12 | 2005-05-10 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
PCT/US2005/016525 WO2005113537A2 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
EP05779448A EP1750704B1 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1750704T3 true PL1750704T3 (pl) | 2010-01-29 |
Family
ID=35169638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05779448T PL1750704T3 (pl) | 2004-05-12 | 2005-05-11 | Pochodne mocznika jako antagoniści receptora P2Y1 użyteczne w leczeniu stanów zakrzepowych |
Country Status (17)
Country | Link |
---|---|
US (1) | US7550499B2 (pl) |
EP (1) | EP1750704B1 (pl) |
JP (1) | JP4795336B2 (pl) |
KR (1) | KR20070011479A (pl) |
CN (2) | CN1984892A (pl) |
AU (1) | AU2005245400A1 (pl) |
CY (1) | CY1109487T1 (pl) |
DE (1) | DE602005015577D1 (pl) |
DK (1) | DK1750704T3 (pl) |
ES (1) | ES2328716T3 (pl) |
HR (1) | HRP20090468T1 (pl) |
MX (1) | MXPA06013024A (pl) |
NO (1) | NO20065544L (pl) |
PL (1) | PL1750704T3 (pl) |
PT (1) | PT1750704E (pl) |
SI (1) | SI1750704T1 (pl) |
WO (1) | WO2005113537A2 (pl) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
US7388021B2 (en) * | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2006078621A2 (en) * | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
WO2007002635A2 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
ATE502924T1 (de) * | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR100858460B1 (ko) * | 2007-05-16 | 2008-09-12 | 최원진 | 장아찌의 제조방법 |
NZ601788A (en) * | 2010-03-01 | 2014-11-28 | Myrexis Inc | Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
MX2013015274A (es) | 2011-06-24 | 2014-03-31 | Amgen Inc | Anatagonista trpm8 y su uso en tratamientos. |
EP2739626B1 (en) | 2011-08-04 | 2016-05-04 | Intervet International B.V. | Novel spiroindoline compounds |
CN103172543B (zh) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | 一种脲类化合物、制备方法及其用途 |
US9428504B2 (en) * | 2012-08-01 | 2016-08-30 | Bristol-Myers Squibb Company | 7-hydroxy-spiropipiperidine indolinyl antagonists of P2Y1 receptor |
EP2892894A1 (en) | 2012-08-01 | 2015-07-15 | Bristol-Myers Squibb Company | 7-hydroxy-indolinyl antagonists of p2y1 receptor |
WO2014022253A1 (en) | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
CN102924442B (zh) * | 2012-11-15 | 2014-10-29 | 沈阳药科大学 | 含有噻唑环的色满类化合物及其类似物和医药用途 |
CN103012381B (zh) * | 2013-01-10 | 2015-01-07 | 山东大学 | 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用 |
CN104402875A (zh) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途 |
GB201721964D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721960D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721961D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721967D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
GB201721957D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
EP4095134A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Polycyclic compounds for the treatment of neurological indications |
EP4094762A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Treatment of neurological indications |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3118888A (en) | 1964-01-21 | Acylated s-triazines and process for their preparation | ||
NL280954A (pl) | 1961-07-14 | |||
US4179563A (en) | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
US4186199A (en) | 1978-11-02 | 1980-01-29 | American Hoechst Corporation | Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines |
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
JPS56166180A (en) | 1980-05-28 | 1981-12-21 | Chugai Pharmaceut Co Ltd | Dibenzoxazepine derivative and its preparation |
JPS56167649A (en) | 1980-05-30 | 1981-12-23 | Chugai Pharmaceut Co Ltd | Diphenyl ether derivative |
JPS5872562A (ja) * | 1981-10-23 | 1983-04-30 | Mitsubishi Chem Ind Ltd | テトラヒドロフタルイミド類 |
US4663453A (en) | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
US4761411A (en) | 1983-05-18 | 1988-08-02 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses |
JPS62280847A (ja) | 1986-05-30 | 1987-12-05 | Konica Corp | 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料 |
US4840947A (en) | 1986-10-14 | 1989-06-20 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas |
JP2577222B2 (ja) | 1987-04-10 | 1997-01-29 | 興和株式会社 | 新規な置換アニリド誘導体 |
JPH0339740A (ja) | 1989-07-06 | 1991-02-20 | Konica Corp | 転写型熱現像カラー感光材料 |
JP2951434B2 (ja) | 1991-04-18 | 1999-09-20 | 三菱製紙株式会社 | 電子写真感光体 |
NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
JP3395285B2 (ja) | 1993-10-06 | 2003-04-07 | 日本製紙株式会社 | 感熱記録体 |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
DE4443641A1 (de) | 1994-12-08 | 1996-06-13 | Bayer Ag | Substituierte Carbonsäureamide |
EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
CN1184425A (zh) | 1995-03-20 | 1998-06-10 | 伊莱利利公司 | 5-取代-3-(1,2,3,6-四氢吡啶-4-基)-和3-(哌啶-4-基)-1h-吲哚:新型5-ht1f激动剂 |
DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
PL329212A1 (en) | 1996-03-25 | 1999-03-15 | Lilly Co Eli | Tetrahydro-beta-carbolynic compounds |
EP0929218A4 (en) | 1996-10-30 | 2001-05-16 | Univ North Carolina | R2Y RECEPTOR ANTAGONISTS |
US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US5858289A (en) | 1997-02-24 | 1999-01-12 | Global Consulting, Inc. | Process for preparing compressed shape of ceramic fiber |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
IL135176A0 (en) | 1997-11-10 | 2001-05-20 | Bristol Myers Squibb Co | Benzothiazole derivatives and pharmaceutical compositions containing the same |
EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
EP1042305B1 (en) | 1997-12-22 | 2005-06-08 | Bayer Pharmaceuticals Corp. | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
WO1999036425A1 (en) * | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
SK18822000A3 (sk) | 1998-07-06 | 2001-12-03 | Bristol-Myers Squibb Company | Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora |
KR20010085852A (ko) | 1998-10-06 | 2001-09-07 | 도모따께 다께시 | 2,3-이치환 피리딘 유도체, 그의 제조방법, 그를 함유하는의약 조성물, 및 그의 제조용 중간체 |
DE69924132T2 (de) | 1998-10-20 | 2006-04-06 | Takeda Pharmaceutical Co. Ltd. | Aromatische aminderivate, verfahren zu ihrer herstellung und mittel, die diese enthalten |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
NZ514711A (en) | 1999-03-12 | 2004-02-27 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
IL144910A0 (en) | 1999-04-15 | 2002-06-30 | Bristol Myers Squibb Co | Cyclic compounds and pharmaceutical compositions containing the same |
CO5200760A1 (es) | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | Antagonistas del receptor de la il-8 ceptor il-8 |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
WO2001023358A1 (fr) | 1999-09-27 | 2001-04-05 | Sagami Chemical Research Center | Derives pyrazole, intermediaires pour la preparation de ces derives, procedes de preparation des derives et intermediaires, et herbicides dont ces derives sont le principe actif |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
WO2001051490A1 (en) | 2000-01-14 | 2001-07-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methanocarba cycloalkyl nucleoside analogues |
EP1254136A4 (en) | 2000-01-29 | 2005-06-01 | Lg Chem Investment Ltd | ARYLAMIDINES AND DERIVATIVES AS FACTOR XA INHIBITORS AND THEIR PRO-PHARMAKA |
JP4574100B2 (ja) * | 2000-02-04 | 2010-11-04 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 血小板adpレセプターインヒビター |
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
MXPA02007632A (es) | 2000-02-07 | 2004-08-23 | Abbott Gmbh & Co Kg | Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. |
WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US6586453B2 (en) | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
ES2261628T3 (es) | 2001-01-31 | 2006-11-16 | P&G-CLAIROL, INC. | Nuevos acopladores para usar en el teñido oxidativo del cabello. |
WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
JP2004538266A (ja) | 2001-04-27 | 2004-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール由来のキナーゼインヒビター |
DE50213703D1 (de) | 2001-05-08 | 2009-09-03 | Bayer Schering Pharma Ag | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
AU2002325381A1 (en) | 2001-07-31 | 2003-02-24 | Bayer Healthcare Ag | Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
MXPA04000920A (es) | 2001-08-06 | 2004-04-02 | Pharmacia Italia Spa | Derivados de aminoisoxazol activos como inhibidores de la cinasa. |
GEP20074098B (en) | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
EP1451156A4 (en) | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOQUINOLINE COMPOUNDS |
EP1461311A2 (en) | 2001-12-26 | 2004-09-29 | Bayer HealthCare AG | Urea derivatives as vr1-antagonists |
JP2003192587A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
WO2003068223A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
DE10213228A1 (de) | 2002-03-25 | 2003-10-16 | Bayer Ag | Cyclopenten-Derivate |
JP4681302B2 (ja) | 2002-05-06 | 2011-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | チアジアゾールまたはオキサジアゾール、およびこれらの、jakプロテインキナーゼのインヒビターとしての使用 |
EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
JP2005537336A (ja) | 2002-08-01 | 2005-12-08 | ニューロサーチ、アクティーゼルスカブ | 抗血管新生治療に応答する疾患の治療に有用な化合物 |
ATE435199T1 (de) | 2002-09-05 | 2009-07-15 | Neurosearch As | Diarylharnstoffderivate und deren verwendung als chloridkanalblocker |
EP1402888A1 (en) | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
TWM252710U (en) | 2003-07-18 | 2004-12-11 | Huei-Chiun Shiu | Annealing equipment |
JPWO2005012221A1 (ja) | 2003-08-04 | 2006-09-14 | 小野薬品工業株式会社 | ジフェニルエーテル化合物、その製造方法および用途 |
MXPA06001638A (es) | 2003-08-13 | 2006-04-28 | Amgen Inc | Antagonistas del receptor de la hormona concentradora de melanina. |
CN101837125B (zh) | 2003-12-26 | 2014-02-26 | 萩原正敏 | Sr蛋白质的磷酸化控制方法以及以包含sr蛋白质活性控制剂的试剂为有效成分的抗病毒剂 |
US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
US7388021B2 (en) | 2004-05-12 | 2008-06-17 | Bristol Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
WO2006078621A2 (en) | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
-
2005
- 2005-05-10 US US11/126,567 patent/US7550499B2/en active Active
- 2005-05-11 DK DK05779448T patent/DK1750704T3/da active
- 2005-05-11 AU AU2005245400A patent/AU2005245400A1/en not_active Abandoned
- 2005-05-11 SI SI200530770T patent/SI1750704T1/sl unknown
- 2005-05-11 MX MXPA06013024A patent/MXPA06013024A/es active IP Right Grant
- 2005-05-11 ES ES05779448T patent/ES2328716T3/es active Active
- 2005-05-11 PT PT05779448T patent/PT1750704E/pt unknown
- 2005-05-11 WO PCT/US2005/016525 patent/WO2005113537A2/en active Application Filing
- 2005-05-11 JP JP2007513323A patent/JP4795336B2/ja not_active Expired - Fee Related
- 2005-05-11 EP EP05779448A patent/EP1750704B1/en active Active
- 2005-05-11 DE DE602005015577T patent/DE602005015577D1/de active Active
- 2005-05-11 CN CNA2005800236206A patent/CN1984892A/zh active Pending
- 2005-05-11 CN CN2005800231306A patent/CN1984655B/zh not_active Expired - Fee Related
- 2005-05-11 KR KR1020067023615A patent/KR20070011479A/ko not_active Application Discontinuation
- 2005-05-11 PL PL05779448T patent/PL1750704T3/pl unknown
-
2006
- 2006-12-01 NO NO20065544A patent/NO20065544L/no not_active Application Discontinuation
-
2009
- 2009-09-03 HR HR20090468T patent/HRP20090468T1/hr unknown
- 2009-10-13 CY CY20091101048T patent/CY1109487T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1750704T1 (sl) | 2009-12-31 |
WO2005113537A3 (en) | 2005-12-22 |
AU2005245400A1 (en) | 2005-12-01 |
HRP20090468T1 (hr) | 2009-09-30 |
CN1984655B (zh) | 2011-11-30 |
EP1750704B1 (en) | 2009-07-22 |
KR20070011479A (ko) | 2007-01-24 |
US7550499B2 (en) | 2009-06-23 |
EP1750704A2 (en) | 2007-02-14 |
US20050261244A1 (en) | 2005-11-24 |
DE602005015577D1 (de) | 2009-09-03 |
WO2005113537A2 (en) | 2005-12-01 |
MXPA06013024A (es) | 2006-12-20 |
NO20065544L (no) | 2006-12-05 |
DK1750704T3 (da) | 2009-11-02 |
ES2328716T3 (es) | 2009-11-17 |
CY1109487T1 (el) | 2012-05-23 |
JP2007537273A (ja) | 2007-12-20 |
CN1984892A (zh) | 2007-06-20 |
PT1750704E (pt) | 2009-10-06 |
JP4795336B2 (ja) | 2011-10-19 |
CN1984655A (zh) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1750704T3 (pl) | Pochodne mocznika jako antagoniści receptora P2Y1 użyteczne w leczeniu stanów zakrzepowych | |
TWI348467B (en) | Nk1 antagonists | |
IL177058A0 (en) | Polyheterocycilic compounds and their use as metabotropic glutamate receptor antagonists | |
TWI318206B (en) | Histamine-3 receptor antagonists | |
IL217453A0 (en) | Diaminopyrimidines as p2x3 and p2x2/3 antagonists | |
IL192309A0 (en) | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists | |
IL184435A0 (en) | Apparatus for use in the construction of buildings | |
ZA200803811B (en) | Neuropolin antagonists | |
ZA200702790B (en) | Thrombin receptor antagonists | |
IL192426A0 (en) | Prokineticin 2 receptor antagonists | |
IL174538A0 (en) | Thrombin receptor antagonists | |
IL177057A0 (en) | Triazole compounds and their use as metabotropic glutamate receptor antagonists | |
PT2260850T (pt) | Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento | |
ZA200708756B (en) | Methods for treating and preventing fibrosis by IL-21R antagonists | |
IL192424A0 (en) | Prokineticin 1 receptor antagonists | |
IL175084A0 (en) | Antagonists of the bradykinin b1 receptor | |
IL179462A0 (en) | Use of the receptor gpr86 | |
ZA200701193B (en) | The use of N-aryl diazaspiracyclic compounds in the treatment of addiction | |
EP1874302A4 (en) | ANTAGONISTS OF ANGIOTENSIN II RECEPTORS | |
IL190686A0 (en) | Il-21 receptor antagonists | |
IL178461A0 (en) | Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | |
IL187426A0 (en) | Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists | |
EP1838730A4 (en) | PAN-HER ANTAGONISTS AND METHODS OF USE | |
EP1812009A4 (en) | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF DISEASES OF THE CNS | |
IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists |